Epilepsy Portfolio And Late Stage Pipeline Are Expected To Drive Long Term Upside

Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause.

Analyst Commentary

Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine. Recent target revisions cluster around updated assumptions for the essential tremor franchise and a reassessment of seizure program contributions to valuation.

Bullish Takeaways

• Bullish analysts see ulixacaltamide as a core value driver for Praxis Precision Medicines, pointing to expectations for multi billion dollar sales in essential tremor and a large, underserved patient pool.
• Several bullish analysts maintain positive ratings and high price targets even after the POWER1 miss, citing secondary data such as the 50% responder rate endpoint, more pronounced seizure reduction at the higher 30 mg dose, and favorable safety as reasons to keep vormatrigine in their models, albeit with lower success probabilities.
• Some research highlights a broader late stage pipeline, including relutrigine in developmental and epileptic encephalopathies and elsunersen in SCN2A epilepsy, as supporting a diversified growth story beyond a single asset.
• One bullish firm characterizes the stock as an attractive entry point after a share price pullback from prior highs. The firm argues that current valuation does not fully reflect the long term revenue potential of the portfolio.

Bearish Takeaways

• Bearish analysts point to the failure of POWER1 to meet its primary endpoint in focal onset seizures as a key overhang. At least one firm has assigned an Underperform rating and a substantially lower price target that implies more conservative expectations for future cash flows.
• Probability of success assumptions for vormatrigine have been cut by some cautious analysts, with one example moving from 60% to 25%. This reduces modeled contribution from the seizure program and weighs on target prices.
• The pause in POWER2 enrollment is viewed as a sign that development for vormatrigine could be slower and more complex than previously anticipated. This raises execution risk and the chance of additional study modifications before any potential regulatory filing.
• While several firms still see a possible path forward for vormatrigine, bearish analysts question how much of the earlier valuation was tied to this asset and whether the current pipeline can fully offset the reduced conviction in the seizure indication without further clinical clarity.

What’s in the News for Praxis Precision Medicines

• FDA grants Breakthrough Therapy Designation to Praxis Precision Medicines' elsunersen (PRAX-222) for seizures associated with SCN2A-DEE caused by gain of function variants, supported by EMBRAVE Part A data showing a 77% sham adjusted reduction in monthly seizure frequency and sustained benefit for up to one year (source: company announcement, FDA designations).
• Praxis Precision Medicines reports EMBRAVE Part A topline results for elsunersen in pediatric SCN2A-DEE, with 71% of treated patients achieving more than 50% seizure reduction, 57% experiencing at least a 28 day period of seizure freedom, and additional improvements in sleep, motor function, muscle tone, attention or neuropsychomotor development, with no drug related serious adverse events (source: EMBRAVE Part A trial update).
• FDA accepts Praxis Precision Medicines' New Drug Application for ulixacaltamide HCl for adult essential tremor, supported by statistically and clinically significant results from the Essential3 Phase 3 program, and sets a PDUFA target action date of January 29, 2027, with no advisory committee planned; ulixacaltamide previously received Breakthrough Therapy Designation in December 2025 (source: NDA acceptance announcement).
• FDA accepts for priority review Praxis Precision Medicines' New Drug Application for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target action date of September 27, 2026, based on the EMBOLD study that was stopped early for efficacy. Relutrigine holds Orphan Drug, Rare Pediatric Disease and Breakthrough Therapy designations and is also being studied in broader DEEs through the EMERALD trial (source: relutrigine NDA and development update).
• Praxis Precision Medicines' Phase 2/3 POWER1 study of vormatrigine in highly refractory focal onset seizures does not meet its primary endpoint for percent change in monthly seizure frequency, although a key secondary 50% response rate endpoint is met and higher 30 mg dosing shows more pronounced seizure reduction. Vormatrigine is generally well tolerated, and Praxis pauses enrollment in the POWER2 trial to reassess the program while most patients transition to the open label extension (source: POWER1 trial results announcement).

Valuation Changes for Praxis Precision Medicines

• Fair Value: The updated blended fair value estimate has risen from $449.13 to $617.67, a change of about 38% that reflects revised modeling assumptions for Praxis Precision Medicines.
• Discount Rate: The discount rate has moved slightly higher from 7.00% to 7.18%, signaling a modest increase in the required return used in the valuation work.
• Revenue Growth: The modeled long term revenue growth contribution has increased from $359.51 to $1,012.81, indicating materially higher assumptions for future dollar revenue in the updated analysis.
• Net Profit Margin: The assumed net profit margin has shifted from 12.36% to 31.51%, suggesting a meaningfully higher projected earnings yield on future dollar sales in the refreshed model.
• Future P/E: The future P/E multiple has moved lower from 188.31x to 59.55x, pointing to a less demanding valuation multiple in the updated scenario work.